Zydus Lifesciences Share Price Target 2022, 2023, 2024, 2025, 2030:- Zydus Life Sciences Headquartered in Ahmedabad, Gujarat India, Zydus Life Sciences operates as an integrated pharmaceutical company with businesses spanning the entire value chain in research, development, manufacturing, marketing and distribution of pharmaceutical products.
With the help of this article, we try to share every aspect of Zydus Lifesciences stock through fundamental and technical analysis.
Zydus Lifesciences Share Price Target 2022
Zydus Life Sciences’ product portfolio includes active pharmaceutical ingredients (APIs) and human formulations. The company’s research and development initiatives span the entire pharmaceutical value chain, including new chemical entities (NCEs), biologics, vaccines, specialty and complex generics, and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including Latin America, Asia Pacific and Africa.
Zydus Life Sciences’ share price target will be available by the end of the financial year 2022. The initial price of Zydus Life Sciences will be around Rs 450. And the second share price of Zydus Life Sciences will be Rs 470.
| Year | Zydus Lifesciences Share Price Target 2022 |
|---|---|
| First Target 2022 | Rs 450 |
| Second Target 2022 | Rs 470 |
Also read:- Granules Share Price Target 2022, 2023, 2024, 2025, 2030
Zydus Life Sciences Share Price Target 2023
Zydus Life Sciences has state-of-the-art, cost-effective and regulated manufacturing facilities to ensure an uninterrupted supply of high-quality products at the most competitive prices to its customers worldwide. The company is one of India’s leading innovation-driven pharmaceutical companies with a presence across the entire pharmaceutical value chain of innovation (R&D), manufacturing, marketing and sales of finished human dosage forms (generic, branded and specialty formulations, including biosimilars and vaccines ), active pharmaceutical ingredients (APIs), animal care products and consumer health products.
Zydus Life Sciences stock price target by the end of 2023. The target value of Zydus Life Sciences’ first shares for the financial year 2023 is estimated to be Rs 550. And the second indicative price of Zydus Life Sciences could offer around Rs 570.
| Year | Zydus Life Sciences Share Price Target 2023 |
|---|---|
| First Target 2023 | Rs 550 |
| Second Target 2023 | Rs 570 |
Also read:- Fortis Healthcare Share Price Target 2022, 2023, 2024, 2025, 2030
Zydus Life Sciences Share Price Target 2024
Innovation is the backbone of the company as it ensures business sustainability through the continuous availability of new products for various businesses. Zydus Lifesciences has launched Lenalidomide Capsules in the US. The company previously received final approvals for the 5 mg, 10 mg, 15 mg and 25 mg strengths, and preliminary approvals for the 2.5 mg and 20 mg strengths. Lenalidomide is used to treat various types of cancer. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug is manufactured at the group’s manufacturing facility in Ahmedabad SEZ, India.
At this time we try to predict the price of two Zydus Life Sciences which will be available in 2024. The first target price of Zydus Life Sciences is Rs 660. And the second target price of Zydus Life Sciences could cross Rs 680.
| Year | Zydus Life Sciences Share Price Target 2024 |
|---|---|
| First Target 2024 | Rs 660 |
| Second Target 2024 | Rs 680 |
Also read:- LCC Infotech Share Price Target 2022, 2023, 2024, 2025, 2030
Zydus Life Sciences Share Price Target 2025
Zydus Life Sciences has acquired the rights to sell MonoFerric injections in India and Nepal from Denmark’s Pharmacosmos A/S. MonoFerric, iron isomaltose 1000 injection/infusion solution, is a rapid single intravenous dose of iron (up to 20 mg/kg body weight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile. MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need for rapid iron delivery. MonoFerric is available in more than 30 countries including the US and Europe, and more than 28 million doses have been administered since its launch.
Two target prices for Zydus Life Sciences stock for FY 2025. The stock price of zydus Life Sciences in FY 2025 will be Rs 770. And the second price target for Zydus Life Sciences for FY2025 will be Rs 800.
| Year | Zydus Life Sciences Share Price Target 2025 |
|---|---|
| First Target 2025 | Rs 770 |
| Second Target 2025 | Rs 800 |
Also read:- Aurobindo Pharma Share Price Target 2022, 2023, 2024, 2025, 2030
Zydus Life Sciences Share Price Target 2030
Zydus Lifesciences has initiated a phase IV clinical trial of Desidustat in patients with anemia caused by chronic kidney disease (CKD). CKD is predicted to become one of the leading causes of premature death worldwide by 2040. An estimated 115.1 million people in India, 132 million in China, 38 million in the United States, 21 million in Japan, and 41 million people in Western Europe are living with chronic kidney disease. The Phase IV DREAM-CKD trial will enroll 1004 CKD patients in India, including 502 dialysis-dependent CKD patients and 502 dialysis-independent CKD anemic patients.
This multicenter post-marketing surveillance study will evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease for 52 weeks, in addition to secondary endpoints including; change in hemoglobin level, changes in lipid profile including small dense LDL, change in weight, change in VEGF, change in serum hepcidin and evaluation of safety laboratory parameters.
The price of the first share target of Zydus Life Sciences will be Rs 1500. And the second target price target for Zydus Life Sciences stock will be Rs 1600 by the end of the financial year 2030.
| Year | Zydus Life Sciences Share Price Target 2030 |
|---|---|
| First Target 2030 | Rs 1500 |
| Second Target 2030 | Rs 1600 |
Also read:- Rallis India Share Price Target 2022, 2023, 2024, 2025, 2030
Future Prospectus of Zydus Life Sciences Share
- Zydus Life Sciences plans to expand its renewable energy portfolio by acquiring existing projects and is also looking for new opportunities in the transmission and distribution sectors.
- In the coming years, Zydus Life Sciences needs to open up and offer its customers and clients more options to do the right thing and continue to help the company make more money annually without distraction.
Zydus Lifesciences Share Price Target 2022, 2023, 2024, 2025, 2030 Table
| Year | Zydus Lifesciences Share Price Target |
|---|---|
| First Target 2022 | Rs 450 |
| Second Target 2022 | Rs 570 |
| First Target 2023 | Rs 550 |
| Second Target 2023 | Rs 570 |
| First Target 2024 | Rs 660 |
| Second Target 2024 | Rs 680 |
| First Target 2025 | Rs 770 |
| Second Target 2025 | Rs 800 |
| First Target 2030 | Rs 1500 |
| Second Target 2030 | Rs 1600 |
Risk of Zydus Life Sciences Share
- Zydus Life Sciences needs additional funding to realize its full potential across the industry, otherwise, Zydus Life Sciences will not be able to provide benefits or returns to its investors for years to come.
- Zydus Life Sciences has a very high debt to the company that needs to be reduced in the coming years or any sales or income they generate annually will be used to cover their debts.
Expert Views on Zydus Life Sciences Share
With all the features related to Zydus Life Sciences, we can say that you should watch this stock for some time and I would say that you need to wait sometime before investing in Zydus Life Sciences stock.
Zydus Life Sciences Share F.A.Q.
– Where is Zydus Life Sciences headquarters located?
Zydus Life Science Headquarters is Located in Ahmedabad, India.
– Who is the current MD of Zydus Life Sciences?
The current MD of Zydus Life Sciences is P. Patel.
– What business is Zydus Life Sciences involved in?
Zydus Lifesciences is a pharmaceutical company based in India. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Conclusion
I hope that after reading the article Zydus Lifesciences Share Price Target 2022, 2023, 2024, 2025, 2030 you must have got a good idea of what kind of performance can be seen in the growth of the Company. If you still have any questions related to this article in your mind, then do not forget to tell me in the comment. Stay tuned to Market in India for important information about this type of stock in the stock market.
Also read:-
